BioVie (NASDAQ:BIVI) vs. Redhill Biopharma (NASDAQ:RDHL) Head-To-Head Comparison

Redhill Biopharma (NASDAQ:RDHL) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Earnings & Valuation

This table compares Redhill Biopharma and BioVie”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290,000.00	14.86	-$430,000.00	$900.00	0.00
BioVie	N/A	N/A	-$17.54 million	($2.45)	-0.73

Redhill Biopharma has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Redhill Biopharma has a beta of 4.98, meaning that its share price is 398% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Redhill Biopharma and BioVie, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1	0	0	0	1.00
BioVie	1	0	0	0	1.00

Institutional and Insider Ownership

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 0.9% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Redhill Biopharma and BioVie’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
BioVie	N/A	-101.15%	-90.18%

Summary

Redhill Biopharma beats BioVie on 9 of the 9 factors compared between the two stocks.

About Redhill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

About BioVie

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.